Merck & Co., Inc. $MRK Shares Acquired by Members Trust Co

Members Trust Co lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 9.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,712 shares of the company’s stock after buying an additional 499 shares during the quarter. Members Trust Co’s holdings in Merck & Co., Inc. were worth $452,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Brighton Jones LLC boosted its holdings in Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after purchasing an additional 8,710 shares during the period. GAMMA Investing LLC boosted its holdings in Merck & Co., Inc. by 12.4% in the first quarter. GAMMA Investing LLC now owns 48,267 shares of the company’s stock worth $4,332,000 after purchasing an additional 5,337 shares during the period. Foundation Wealth Management LLC PA boosted its holdings in Merck & Co., Inc. by 2.4% in the first quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company’s stock worth $481,000 after purchasing an additional 127 shares during the period. Asset Management One Co. Ltd. boosted its holdings in Merck & Co., Inc. by 1.8% in the first quarter. Asset Management One Co. Ltd. now owns 1,292,621 shares of the company’s stock worth $116,026,000 after purchasing an additional 22,556 shares during the period. Finally, Palisade Asset Management LLC boosted its holdings in Merck & Co., Inc. by 1.2% in the first quarter. Palisade Asset Management LLC now owns 33,356 shares of the company’s stock worth $2,994,000 after purchasing an additional 385 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $87.61 on Wednesday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $107.36. The firm’s 50-day simple moving average is $84.18 and its 200 day simple moving average is $81.39. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The stock has a market cap of $218.83 billion, a P/E ratio of 13.50, a P/E/G ratio of 0.95 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The business had revenue of $15.81 billion for the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Citigroup assumed coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. Wells Fargo & Company decreased their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Finally, Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their target price for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.